# US 2024/0002852 A1 · Compounds for modulating chmp7

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002852 A1
- Document ID: US20240002852A1
- Status: Published application
- Kind: A1
- Application number: 18/247,311
- Filed: 2021-10-01
- Published: 2024-01-04
- Earliest claimed: 2020-10-01
- Assignees: Ionis Pharmaceuticals, Inc.
- Applicants: Ionis Pharmaceuticals, Inc.
- Inventors: Huynh-Hoa Bui
- Web page: https://patentgrep.com/patent/US20240002852A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 2310/11: Antisense
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are compounds and pharmaceutical compositions for reducing the amount or activity of Charged Multivesicular Body Protein 7 (CHMP7) RNA in a cell or subject, and in certain instances reducing the amount of CHMP7 protein in a cell or subject. Such compounds and pharmaceutical compositions are useful to ameliorate diseases or conditions associated with aberrant activation of Endosomal Sorting Complexes Required for Transport-III proteins.

## Claims

### Claim 1

An oligomeric compound comprising a modified oligonucleotide consisting of 12 to 50 linked nucleosides wherein the nucleobase sequence of the modified oligonucleotide is at least 90% complementary to an equal length portion of a CHMP7 nucleic acid, and wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified internucleoside linkage.

### Claim 2

An oligomeric compound comprising a modified oligonucleotide consisting of 12 to 50 linked nucleosides and having a nucleobase sequence comprising at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or 20 contiguous nucleobases of any of the nucleobases of SEQ ID NOs: 10-477, wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified internucleoside linkage.

### Claim 3 (depends on 2)

The oligomeric compound of claim 2, wherein the modified oligonucleotide has a nucleobase sequence consisting of the nucleobase sequence of any of SEQ ID NOs: 10-477.

### Claim 4

An oligomeric compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 contiguous nucleobases complementary to:
an equal length portion within nucleobases 3950-3983 of SEQ ID NO: 1;
an equal length portion within nucleobases 4242-4266 of SEQ ID NO: 1;
an equal length portion within nucleobases 4480-4525 of SEQ ID NO: 1;
an equal length portion within nucleobases 4534-4566 of SEQ ID NO: 1;
an equal length portion within nucleobases 5205-5232 of SEQ ID NO: 1;
an equal length portion within nucleobases 5404-5430 of SEQ ID NO: 1;
an equal length portion within nucleobases 8323-8344 of SEQ ID NO: 1;
an equal length portion within nucleobases 16927-16950 of SEQ ID NO: 1;
an equal length portion within nucleobases 17298-17340 of SEQ ID NO: 1; or
an equal length portion within nucleobases 18287-18313 of SEQ ID NO: 1;
wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified internucleoside linkage.

### Claim 5

An oligomeric compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, or at least 18 contiguous nucleobases of a sequence selected from:
SEQ ID NOs: 220, 302, and 345;
SEQ ID NOs: 21, 131, 191, and 465;
SEQ ID NOs: 34, 116, 184, 242, 257, 340, and 474;
SEQ ID NOs: 55, 118, 202, 267, 372, and 422;
SEQ ID NOs: 73, 136, 197, and 421;
SEQ ID NOs: 79, 160, 168, 230, 313, 331, and 464;
SEQ ID NOs: 157, 186, and 265;
SEQ ID NOs: 128, 182, and 309;
SEQ ID NOs: 44, 76, 153, 206, 283, 363, and 416; or
SEQ ID NOs: 85, 121, 189, 300, and 354;
wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified internucleoside linkage.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The oligomeric compound of any of claims 1-5, wherein the modified oligonucleotide has a nucleobase sequence that is at least 80%, 85%, 90%, 95%, or 100% complementary to the nucleobase sequence of SEQ ID NO: 1 or SEQ ID NO: 2 when measured across the entire nucleobase sequence of the modified oligonucleotide.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The oligomeric compound of any of claims 1-6, wherein the modified oligonucleotide comprises at least one modified nucleoside.

### Claim 8 (depends on 7)

The oligomeric compound of claim 7, wherein the modified oligonucleotide comprises at least one modified nucleoside comprising a modified sugar moiety.

### Claim 9 (depends on 8)

The oligomeric compound of claim 8, wherein the modified oligonucleotide comprises at least one modified nucleoside comprising a bicyclic sugar moiety.

### Claim 10 (depends on 9)

The oligomeric compound of claim 9, wherein the modified oligonucleotide comprises at least one modified nucleoside comprising a bicyclic sugar moiety having a 2′-4′ bridge, wherein the 2′-4′ bridge is selected from —O—CH2—; and —O—CH(CH3)—.

### Claim 11 (depends on 7, 8, 9, 10)

The oligomeric compound of any of claims 7-10, wherein the modified oligonucleotide comprises at least one modified nucleoside comprising a non-bicyclic modified sugar moiety.

### Claim 12 (depends on 11)

The oligomeric compound of claim 11, wherein the modified oligonucleotide comprises at least one modified nucleoside comprising a non-bicyclic modified sugar moiety comprising a 2′-MOE modified sugar moiety or a 2′-OMe modified sugar moiety.

### Claim 13 (depends on 7, 8, 9, 10, 11, 12)

The oligomeric compound of any of claims 7-12, wherein the modified oligonucleotide comprises at least one modified nucleoside comprising a sugar surrogate.

### Claim 14 (depends on 13)

The oligomeric compound of claim 13, wherein the sugar surrogate is selected from any of morpholino, modified morpholino, PNA, THP, and F-HNA.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 13, 14)

The oligomeric compound of any of claim 1-8 or 11-14, wherein the modified oligonucleotide does not comprise a bicyclic modified sugar moiety.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The oligomeric compound of any of claims 1-15, wherein the modified oligonucleotide is a gapmer.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The oligomeric compound of any of claims 1-16 wherein the modified oligonucleotide comprises a deoxy region consisting of 5-12 linked 2′-deoxynucleosides.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The oligomeric compound of any of claims 1-16, wherein the modified oligonucleotide comprises a deoxy region consisting of 5-12 linked 2′-β-D-deoxynucleosides.

### Claim 19 (depends on 17, 18)

The oligomeric compound of claim 17 or claim 18, wherein the deoxy region consists of 6, 7, 8, 9, 10, or 6-10 linked nucleosides.

### Claim 20 (depends on 17, 18, 19)

The oligomeric compound of any of claims 17-19, wherein each nucleoside immediately adjacent to the deoxy region comprises a modified sugar moiety.

### Claim 21 (depends on 17, 18, 19, 20)

The oligomeric compound of any of claims 17-20, wherein the deoxy region is flanked on the 5′-side by a 5′-external region consisting of 1-6 linked 5′-external region nucleosides and on the 3′-side by a 3′-external region consisting of 1-6 linked 3′-external region nucleosides; wherein
the 3′-most nucleoside of the 5′ external region comprises a modified sugar moiety; and
the 5′-most nucleoside of the 3′ external region comprises a modified sugar moiety.

### Claim 22 (depends on 21)

The oligomeric compound of claim 21, wherein each nucleoside of the 3′ external region comprises a modified sugar moiety.

### Claim 23 (depends on 21, 22)

The oligomeric compound of claim 21 or claim 22, wherein each nucleoside of the 5′ external region comprises a modified sugar moiety.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The oligomeric compound of any of claims 1-23, wherein the modified oligonucleotide comprises:
a 5′-region consisting of 1-7 linked 5′-region nucleosides;
a central region consisting of 6-10 linked central region nucleosides; and
a 3′-region consisting of 1-7 linked 3′-region nucleosides; wherein
each of the 5′-region nucleosides and each of the 3′-region nucleosides comprises a modified sugar moiety and each of the central region nucleosides comprises a 2′-β-D-deoxyfuranosyl sugar moiety.

### Claim 25 (depends on 24)

The oligomeric compound of claim 24, wherein the modified oligonucleotide comprises:
a 5′-region consisting of 5 linked 5′-region nucleosides;
a central region consisting of 10 linked central region nucleosides; and
a 3′-region consisting of 5 linked 3′-region nucleosides; wherein
each of the 5′-region nucleosides and each of the 3′-region nucleosides is a 2′-MOE nucleoside and each of the central region nucleosides is a 2′-β-D-deoxynucleoside.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The oligomeric compound of any of claims 1-25, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.

### Claim 27 (depends on 26)

The oligomeric compound of claim 26, wherein each internucleoside linkage of the modified oligonucleotide is a modified internucleoside linkage.

### Claim 28 (depends on 26, 27)

The oligomeric compound of claim 26 or claim 27 wherein at least one modified internucleoside linkage is a phosphorothioate internucleoside linkage.

### Claim 29 (depends on 26, 28)

The oligomeric compound of claim 26 or claim 28 wherein the modified oligonucleotide comprises at least one phosphodiester internucleoside linkage.

### Claim 30 (depends on 26, 28)

The oligomeric compound of any of claim 26, 28, or 29, wherein each internucleoside linkage is either a phosphodiester internucleoside linkage or a phosphorothioate internucleoside linkage.

### Claim 31 (depends on 27)

The oligomeric compound of claim 27, wherein each modified internucleoside linkage is a phosphorothioate internucleoside linkage

### Claim 32 (depends on 26)

The oligonucleotide compound of claim 26, wherein the modified oligonucleotide has an internucleoside linkage motif of soooossssssssssooss; wherein,
s=a phosphorothioate internucleoside linkage and o=a phosphodiester internucleoside linkage.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The oligomeric compound of any of claims 1-32, wherein the modified oligonucleotide comprises at least one modified nucleobase.

### Claim 34 (depends on 33)

The oligomeric compound of claim 33, wherein the modified nucleobase is a 5-methyl cytosine.

### Claim 35 (depends on 34)

The oligomeric compound of claim 34, wherein each cytosine is a 5-methyl cytosine.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The oligomeric compound of any of claims 1-35, wherein the modified oligonucleotide consists of 12-30, 12-22, 12-20, 14-18, 14-20, 15-17, 15-25, 16-18, 16-20, 17-20, 18-20 or 18-22 linked nucleosides.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The oligomeric compound of any of claims 1-36, wherein the modified oligonucleotide consists of 16, 17, 18, 19, or 20 linked nucleosides.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The oligomeric compound of any of claims 1-35, wherein the modified oligonucleotide consists of 20 linked nucleosides.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The oligomeric compound of any of claims 1-38, consisting of the modified oligonucleotide.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The oligomeric compound of any of claims 1-38, wherein the oligomeric compound comprises a conjugate group.

### Claim 41 (depends on 40)

The oligomeric compound of claim 40, wherein the conjugate group comprises a conjugate moiety and a conjugate linker.

### Claim 42 (depends on 41)

The oligomeric compound of claim 41, wherein the conjugate linker consists of a single bond.

### Claim 43 (depends on 41, 42)

The oligomeric compound of claim 41 or claim 42, wherein the conjugate linker is cleavable.

### Claim 44 (depends on 41, 43)

The oligomeric compound of claim 41 or claim 43, wherein the conjugate linker comprises 1-3 linker-nucleosides.

### Claim 45 (depends on 41, 42, 43)

The oligomeric compound of any of claims 41-43, wherein the conjugate linker does not comprise any linker nucleosides.

### Claim 46 (depends on 40, 41, 42, 43, 44, 45)

The oligomeric compound of any of claims 40-45, wherein the conjugate group is attached to the modified oligonucleotide at the 5′-end of the modified oligonucleotide.

### Claim 47 (depends on 40, 41, 42, 43, 44, 45)

The oligomeric compound of any of claims 40-45, wherein the conjugate group is attached to the modified oligonucleotide at the 3′-end of the modified oligonucleotide.

### Claim 48 (depends on 40, 41, 42, 43, 44, 45, 46, 47)

The oligomeric compound of any of claims 40-47, wherein the conjugate group comprises a lipid.

### Claim 49 (depends on 40, 41, 42, 43, 44, 45, 46, 47)

The oligomeric compound of any of claims 40-47, wherein the conjugate group comprises a cell-targeting moiety.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The oligomeric compound of any of claims 1-49, further comprising a terminal group.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The oligomeric compound of any of claims 1-49, wherein the oligomeric compound is a singled-stranded oligomeric compound.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The oligomeric compound of any of claims 1-51, wherein the oligomeric compound is capable of reducing the amount of CHMP7 RNA in a cell.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The oligomeric compound of any of claims 1-52, wherein the modified oligonucleotide of the oligomeric compound is a pharmaceutically acceptable salt comprising one or more cations selected from sodium, potassium, calcium, and magnesium.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

An oligomeric duplex, comprising a first oligomeric compound and a second oligomeric compound comprising a second modified oligonucleotide, wherein the first oligomeric compound is an oligomeric compound of any of claims 1-53.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

An antisense agent comprising an antisense compound, wherein the antisense compound is the oligomeric compound of any of claims 1-53 or the oligomeric duplex of claim 54.

### Claim 56 (depends on 54, 55)

The antisense agent of claim 55, wherein the antisense agent is the oligomeric duplex of claim 54

### Claim 57 (depends on 55, 56)

The antisense agent of claim 55 or claim 56, wherein the antisense agent is:
an RNase H agent capable of reducing the amount of CHMP7 nucleic acid through the activation of RNase H; or
an RNAi agent capable of reducing the amount of CHMP7 nucleic acid through the activation of RISC/Ago2.

### Claim 58 (depends on 55, 56, 57)

The antisense agent of any of claims 55-57, wherein the antisense agent comprises a conjugate group, wherein the conjugate group comprises a cell-targeting moiety.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

A pharmaceutical composition comprising the oligomeric compound of any of claims 1-53, the oligomeric duplex of claim 54, or the antisense agent of any of claims 55-58, and a pharmaceutically acceptable diluent.

### Claim 60 (depends on 59)

The pharmaceutical composition of claim 59, wherein the pharmaceutically acceptable diluent is artificial CSF (aCSF) or phosphate-buffered saline (PBS).

### Claim 61 (depends on 60)

The pharmaceutical composition of claim 60, wherein the pharmaceutical composition consists essentially of the oligomeric compound, oligomeric duplex, or antisense agent, and artificial CSF (aCSF).

### Claim 62 (depends on 60)

The pharmaceutical composition of claim 60, wherein the pharmaceutical composition consists essentially of the oligomeric compound, oligomeric duplex, or antisense agent, and phosphate buffered saline (PBS).

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

A chirally enriched population of oligomeric compounds of any of claims 1-53, wherein the population is enriched for oligomeric compounds comprising at least one particular phosphorothioate internucleoside linkage having a particular stereochemical configuration.

### Claim 64 (depends on 63)

The chirally enriched population of claim 63, wherein the population is enriched for oligomeric compounds comprising at least one particular phosphorothioate internucleoside linkage having the (Sp) configuration.

### Claim 65 (depends on 63)

The chirally enriched population of claim 63, wherein the population is enriched for oligomeric compounds comprising at least one particular phosphorothioate internucleoside linkage having the (Rp) configuration.

### Claim 66 (depends on 63)

The chirally enriched population of claim 63, wherein the population is enriched for oligomeric compounds having a particular, independently selected stereochemical configuration at each phosphorothioate internucleoside linkage.

### Claim 67 (depends on 66)

The chirally enriched population of claim 66, wherein the population is enriched for oligomeric compounds having the (Sp) configuration at each phosphorothioate internucleoside linkage or for modified oligonucleotides having the (Rp) configuration at each phosphorothioate internucleoside linkage.

### Claim 68 (depends on 66)

The chirally enriched population of claim 66, wherein the population is enriched for oligomeric compounds having the (Rp) configuration at one particular phosphorothioate internucleoside linkage and the (Sp) configuration at each of the remaining phosphorothioate internucleoside linkages.

### Claim 69 (depends on 66)

The chirally enriched population of claim 66, wherein the population is enriched for oligomeric compounds having at least 3 contiguous phosphorothioate internucleoside linkages in the Sp, Sp, and Rp configurations, in the 5′ to 3′ direction.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

A population of oligomeric compounds of any of claims 1-53, wherein all of the phosphorothioate internucleoside linkages of the modified oligonucleotide are stereorandom.

### Claim 71 (depends on 63, 64, 65, 66, 67, 68, 69, 70)

A pharmaceutical composition comprising the population of oligomeric compounds of any of claims 63-70 and a pharmaceutically acceptable diluent.

### Claim 72 (depends on 71)

The pharmaceutical composition of claim 71, wherein the pharmaceutically acceptable diluent is artificial CSF (aCSF) or phosphate-buffered saline (PBS).

### Claim 73 (depends on 72)

The pharmaceutical composition of claim 72, wherein the pharmaceutical composition consists essentially of the population of oligomeric compounds and artificial CSF (aCSF).

### Claim 74 (depends on 72)

The pharmaceutical composition of claim 72, wherein the pharmaceutical composition consists essentially of the population of oligomeric compounds and PBS.
